AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

(in millions, except per share data)	Quarter Ended March 31, 2024						Full-Year Ended December 31, 2024
	Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range				Acquired IPR&D and Milestones Expense		Adjusted Diluted EPS Range
			Low		High				Low		High
Previously announced guidance excluding Q1 2024 acquired IPR&D and milestones expense	$	—	$	2.26	$	2.30	$	—	$	11.05	$	11.25
Q1 2024 acquired IPR&D and milestones expense	164		(0.08)		(0.08)		164		(0.08)		(0.08)
Guidance including Q1 2024 acquired IPR&D and milestones expensea	$	164	$	2.18	$	2.22	$	164	$	10.97	$	11.17

a    The Company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2024, as both cannot be reliably forecasted.

    1